% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Stetefeld:172852,
      author       = {Stetefeld, Henning R. and Lehmann, Helmar C. and Fink,
                      Gereon R. and Burghaus, Lothar},
      title        = {{P}osterior {R}eversible {E}ncephalopathy {S}yndrome and
                      {S}troke after {I}ntravenous {I}mmunoglobulin {T}reatment in
                      {M}iller–{F}isher {S}yndrome/{B}ickerstaff {B}rain {S}tem
                      {E}ncephalitis {O}verlap {S}yndrome},
      journal      = {Journal of stroke and cerebrovascular diseases},
      volume       = {23},
      number       = {9},
      issn         = {1052-3057},
      address      = {New York, NY},
      publisher    = {Elsevier},
      reportid     = {FZJ-2014-06286},
      pages        = {e423 - e425},
      year         = {2014},
      abstract     = {The association of a posterior reversible encephalopathy
                      syndrome (PRES) without arterial hypertension with
                      autoimmune-mediated inflammatory neuropathies such as
                      Guillain–Barré syndrome (GBS) is a rare and poorly
                      understood phenomenon. To date, PRES has been described as
                      initial manifestation, coincidental finding, or adverse
                      event subsequent to immunomodulatory treatment with
                      intravenous immunoglobulin (IVIG) in cases of axonal and
                      demyelinating GBS as well as in Miller–Fisher syndrome
                      (MFS). We here report a case of MFS/Bickerstaff brain stem
                      encephalitis (BBE)–overlap syndrome and nonhypertensive
                      PRES that occurred in close temporal association with IVIG
                      treatment and caused stroke. Immunoadsorption ameliorated
                      the disease course. Our case supports the notion that in
                      severe cases, immunoadsorption should be considered as
                      first-line therapy instead of IVIG for rapid removal of IgG
                      and thus to hasten recovery and improve functional outcome.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {333 - Pathophysiological Mechanisms of Neurological and
                      Psychiatric Diseases (POF2-333) / 89572 - (Dys-)function and
                      Plasticity (POF2-89572)},
      pid          = {G:(DE-HGF)POF2-333 / G:(DE-HGF)POF2-89572},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000345649900003},
      doi          = {10.1016/j.jstrokecerebrovasdis.2014.05.034},
      url          = {https://juser.fz-juelich.de/record/172852},
}